BACKGROUND AND OBJECTIVES: Podocyte loss is key in glomerulosclerosis. Activated parietal epithelial cells are proposed to contribute to pathogenesis of glomerulosclerosis and may serve as stem cells that can transition to podocytes. CD44 is a marker for activated parietal epithelial cells. This study investigated whether activated parietal epithelial cells are increased in early recurrent FSGS in transplant compared with minimal change disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: CD44 staining in renal allograft biopsies from 12 patients with recurrent FSGS was performed and compared with native kidneys with minimal change disease or FSGS and normal control native and transplant kidneys without FSGS. CD44+ epithelial cells along Bowman's capsule in the parietal epithelial cell location and over the glomerular tuft in the visceral epithelial cell location were assessed. RESULTS: Cases with early recurrent FSGS manifesting only foot process effacement showed significantly increased CD44+ visceral epithelial cells involving 29.0% versus 2.6% of glomeruli in minimal change disease and 0% in non-FSGS transplants. Parietal location CD44 positivity also was numerically increased in recurrent FSGS. In later transplant biopsies, glomeruli with segmental lesions had more CD44+ visceral epithelial cells than glomeruli without lesions. CONCLUSIONS: Parietal epithelial cell activation marker is significantly increased in evolving FSGS versus minimal change disease, and this increase may distinguish early FSGS from minimal change disease. Whether parietal epithelial cell activation contributes to pathogenesis of sclerosis in idiopathic FSGS or is a regenerative/repair response to replace injured podocytes awaits additional study.
BACKGROUND AND OBJECTIVES: Podocyte loss is key in glomerulosclerosis. Activated parietal epithelial cells are proposed to contribute to pathogenesis of glomerulosclerosis and may serve as stem cells that can transition to podocytes. CD44 is a marker for activated parietal epithelial cells. This study investigated whether activated parietal epithelial cells are increased in early recurrent FSGS in transplant compared with minimal change disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: CD44 staining in renal allograft biopsies from 12 patients with recurrent FSGS was performed and compared with native kidneys with minimal change disease or FSGS and normal control native and transplant kidneys without FSGS. CD44+ epithelial cells along Bowman's capsule in the parietal epithelial cell location and over the glomerular tuft in the visceral epithelial cell location were assessed. RESULTS: Cases with early recurrent FSGS manifesting only foot process effacement showed significantly increased CD44+ visceral epithelial cells involving 29.0% versus 2.6% of glomeruli in minimal change disease and 0% in non-FSGS transplants. Parietal location CD44 positivity also was numerically increased in recurrent FSGS. In later transplant biopsies, glomeruli with segmental lesions had more CD44+ visceral epithelial cells than glomeruli without lesions. CONCLUSIONS: Parietal epithelial cell activation marker is significantly increased in evolving FSGS versus minimal change disease, and this increase may distinguish early FSGS from minimal change disease. Whether parietal epithelial cell activation contributes to pathogenesis of sclerosis in idiopathic FSGS or is a regenerative/repair response to replace injured podocytes awaits additional study.
Authors: Jaakko Patrakka; Vesa Ruotsalainen; Ilkka Ketola; Christer Holmberg; Markku Heikinheimo; Karl Tryggvason; Hannu Jalanko Journal: J Am Soc Nephrol Date: 2001-02 Impact factor: 10.121
Authors: Juergen Strehlau; Asher D Schachter; Martha Pavlakis; Anup Singh; Amir Tejani; Terry B Strom Journal: Kidney Int Date: 2002-01 Impact factor: 10.612
Authors: Bart Smeets; Nathalie A J M Te Loeke; Henry B P M Dijkman; Mark L M Steenbergen; Joost F M Lensen; Mark P V Begieneman; Toin H van Kuppevelt; Jack F M Wetzels; Eric J Steenbergen Journal: J Am Soc Nephrol Date: 2004-04 Impact factor: 10.121
Authors: Christoph Kuppe; Hermann-Josef Gröne; Tammo Ostendorf; Toin H van Kuppevelt; Peter Boor; Jürgen Floege; Bart Smeets; Marcus J Moeller Journal: Kidney Int Date: 2015-04-08 Impact factor: 10.612
Authors: Samy Hakroush; Angelika Cebulla; Thomas Schaldecker; Daniel Behr; Peter Mundel; Astrid Weins Journal: J Am Soc Nephrol Date: 2013-12-12 Impact factor: 10.121
Authors: Natalya V Kaverina; Diana G Eng; Benjamin S Freedman; J Nathan Kutz; Tyler J Chozinski; Joshua C Vaughan; Jeffrey H Miner; Jeffrey W Pippin; Stuart J Shankland Journal: Kidney Int Date: 2019-03-29 Impact factor: 10.612
Authors: Jiong Zhang; Jeffrey W Pippin; Ronald D Krofft; Shokichi Naito; Zhi-Hong Liu; Stuart J Shankland Journal: Am J Physiol Renal Physiol Date: 2013-03-13
Authors: Bairbre A McNicholas; Diana G Eng; Julia Lichtnekert; Peter S Rabinowitz; Jeffrey W Pippin; Stuart J Shankland Journal: Am J Physiol Renal Physiol Date: 2016-07-20